{
  "id": 16582143,
  "title": "Neoadjuvant durvalumab plus chemotherapy in resectable or borderline resectable non-small-cell lung cancer: the phase 2 MDT-BRIDGE trial",
  "url": "https://urgent.news/2026/10/26/neoadjuvant-durvalumab-plus-chemotherapy-in-resectable-or-borderline",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-26T00:00:00.000Z",
  "source": {
    "name": "Nature Medicine",
    "slug": "nature-medicine",
    "url": "https://www.nature.com/articles/s41591-026-04742-7"
  },
  "original_language": "en",
  "account": null,
  "summary": "Nature Medicine, Published online: 26 October 2026; doi:10.1038/s41591-026-04742-7 As presented at the ESMO Congress 2026: In the global phase 2 MDT-BRIDGE trial, neoadjuvant durvalumab plus chemotherapy in patients with resectable and borderline resectable non-small-cell lung cancer, followed by multidisciplinary reassessment, enabled surgery in most patients, leading to encouraging pathological…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}